Raymond James initiated coverage on Catalyst Biosciences with a new price target
$CBIO
Raymond James initiated coverage of Catalyst Biosciences with a rating of Outperform and set a new price target of $18.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/15/2021 | Outperform → Market Perform | Raymond James | |
| 8/6/2021 | $19.00 → $18.00 | Outperform | Raymond James |
8-K - GYRE THERAPEUTICS, INC. (0001124105) (Filer)
8-K/A - GYRE THERAPEUTICS, INC. (0001124105) (Filer)
8-K/A - GYRE THERAPEUTICS, INC. (0001124105) (Filer)
4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
Advancing Lead Program, CR-001, a PD-1 x VEGF Bispecific Antibody, and Developing Pipeline of Novel ADCs as Single Agents and in Combination with CR-001 On Track to Submit IND Application for CR-001 in Fourth Quarter of 2025 with Proof-of-Concept Clinical Data Expected in Second Half of 2026 Shares to Begin Trading on Nasdaq Under Ticker Symbol "CBIO" Today, June 16 WALTHAM, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company"), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced the completion of its previously announced merger with GlycoMimetics, Inc. ("GlycoMimetics"). The com
EMERYVILLE, Calif., Dec. 15, 2023 /PRNewswire/ -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent libraries and AI tools, announced today that Nassim Usman, Ph.D., has been named President & Chief Executive Officer and closed a $66M Series B financing led by DCVC Bio. Neil Dhawan, Ph.D, Totus co-founder, founding CEO, and CSO, will transition into a new role as CSO and Head of R&D, where he will continue to oversee the company's platform, programs, and data. "We are thrilled by Nassim's arrival," said DCVC Bio Managing Pa
The combined company will operate as "Gyre Therapeutics, Inc." with its common stock traded on Nasdaq under trading symbol "GYRE" effective Tuesday, October 31, 2023 SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) ("Catalyst") today announced completion of the business combination with GNI Group Ltd. and related entities. Catalyst received stockholder approval for all proposals necessary to complete the business combination at a special meeting of stockholders held on August 29, 2023. Catalyst effected a name change and a reverse stock split of Catalyst's common stock immediately prior to the closing of the business combination. The combined company w
Raymond James downgraded Catalyst Biosciences from Outperform to Market Perform
Raymond James reiterated coverage of Catalyst Biosciences with a rating of Outperform and set a new price target of $18.00 from $19.00 previously
Stephens resumed coverage of Catalyst Biosciences with a rating of Overweight and set a new price target of $19.00 from $18.00 previously